参麦注射液治疗慢性呼吸衰竭急性加重患者的临床效果

Clinical Efficacy of SMI on the Treatment of Acute Exacerbation of Chronic Respiratory Failure

目的:探讨参麦注射液用于治疗慢性呼吸衰竭急性加重患者的临床效果。方法:选取2011年3月-2012年6月在我愿接受治疗的慢性呼吸衰竭急性加重的患者68例,随机分为参麦组和对照组,每组各34例。对照组采取常规方法进行治疗,参麦组在此基础上给予参麦注射液加以治疗。观察并比较两组患者的治愈率、住院时间、肺功能指标(FEV1)及血气分析情况等相关指标。结果:参麦组的治愈率为91.18%,与对照组的53.12%相比较,差异显著(X2=10.8800,P<0.05)。参麦组的住院时间显著短于对照组,其肺功能指标、血气分析结果包括氧分压值和二氧化碳分压值均明显优于对照组,具有统计学意义(P<0.05)。结论:参麦注射液治疗慢性呼吸衰竭急性加重疾病不失为一种优良的治疗方案,不仅患者临床症状得到明显的改善,病情好转加快,还可以调节患者的免疫力,在临床上值得推广。

Objective： To explore the clinical effects of Shenmai Injection （SMI） on the treatment of acute exacerbation of chronic respiratory failure. Methods： 68 patients with acute exacerbation of chronic respiratory failure who were treated in our hospital from March 2011 to June 2012 were selected and randomly divided into the SMI group and the control group with 34 cases in each group. The patients in the control group were treated by the conventional method, while the patients in the SMI group was treated with SMI besides the conventional treatment. The cure rate, the hospitalization, lung function （FEV1） and the blood gas analysis of patients in the two groups were observed and analyzed. Results： The cure rate of SMI group was 91.18%, which was higher than that of the control group with the statistically significant differences （Xz=- 10.8800, P 〈0.05）; The hospitalization time of SMI group was significantly shorter than that of the control group, and the pulmonary function, blood gas analysis results including POz and PCO2 values were both significantly better than those of the control group with statistical significance （P 〈0.05）. Conclusion： The effects of SMI on the treatment of acute exacerbation of chronic respiratory failure disease which was regarded as a good treatment program, it was not only improved with clinical symptoms significantly in patients, and got better, faster, but also adjust the patient＇s immune system, and can be promoted in clinical practice.